313368-91-1

Basic information

• Product Name: ITI-722
• Synonyms: ITI-722;Lumateperone
• CAS NO: 313368-91-1
• Molecular Formula: C₂₄H₂₈FN₃O
• Molecular Weight: 393.4970232
• Product Categories: API
• Mol File: 313368-91-1.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 556.4±50.0 °C(Predicted)
• Appearance: /
• Density: 1.26±0.1 g/cm3(Predicted)
• PKA: 9.10±0.20(Predicted)
• CAS DataBase Reference: ITI-722(CAS DataBase Reference)
• NIST Chemistry Reference: ITI-722(313368-91-1)
• EPA Substance Registry System: ITI-722(313368-91-1)

Safety Data

• Hazardous Substances Data: 313368-91-1(Hazardous Substances Data)

Usage

Description

ITI-722, also known as Lumateperone, is a novel antipsychotic agent with a unique mechanism of action characterized by high 5-hydroxytryptamine 2A (5-HT2A) receptor blocking activity. It has demonstrated efficacy in the treatment of schizophrenia and may have potential applications in bipolar depression. Additionally, a Phase 2 study revealed strong evidence of its efficacy in treating insomnia without impairing next-day cognition.

Uses

Used in Pharmaceutical Industry:
ITI-722 is used as an antipsychotic agent for the treatment of schizophrenia, offering a unique mechanism of action that targets the 5-HT2A receptors.
ITI-722 is also used as a potential treatment for bipolar depression, given its unique pharmacological profile.
Used in Sleep Aid Industry:
ITI-722 is used as a sleep aid for the treatment of insomnia, as demonstrated in a Phase 2 study that showed its efficacy in improving sleep quality without affecting next-day cognition.

Upstream product

• 313369-67-4 3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline 
• 3874-54-2 4-(4-fluorophenyl)-4-oxo-n-butyl chloride 
• 313368-85-3 (6bR,10aS)-3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido-[3’,4’:4,5]-pyrrolo[1,2,3-de]quinoxaline 
• 59564-59-9 1,2,3,4-tetrahydroquinoxalin-2-one 
• 53374-52-0 1-nitroso-3-keto-1,2,3,4-tetrahydroquinoxaline 
• 313544-31-9 2-oxo-2,3,9,10-tetrahydro-1H,7H-pyrido-[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline-8-carboxylic acid ethyl ester 
• 87973-61-3 1-amino-3-keto-1,2,3,4-tetrahydroquinoxaline 
• 50709-33-6 2-bromophenylhydrazine hydrochloride 
• 1059630-11-3 6-bromo-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole hydrochloric acid salt 
• 40064-34-4 piperidine-4,4-diol hydrochloride 
• 40862-32-6 1-iodo-3-(p-fluorophenylcarbonyl)propane 

Downstream Products

• 1187020-80-9 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt 

Relevant articles and documents

ORGANIC COMPOUND

The invention relates to a particular substituted heterocycle fused gamma-carboline, in free, or pharmaceutically acceptable salt, and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), and/or pathways involving the dopamine D1 and D2 receptor signaling system.

SOLID STATE FORMS OF LUMATEPERONE SALTS AND PROCESSES FOR PREPARATION OF LUMATEPERONE AND SALTS THEREOF

The present disclosure relates to solid state forms of Lumateperone besylate, processes for preparation thereof and pharmaceutical compositions thereof.

METHOD FOR THE MANUFACTURE OF LUMATEPERONE AND ITS SALTS

Method for the production of formula (I) lumateperone or its acid addition salts so that the enantiomer compound with stereochemistry 6bR, 10aS is separated form the cis racemate using resolution and the formula (II) stereoisomer is alkylated with 4-halo-4'-fluoro butyrophenone (X = I, Br, CI) to produce the formula (I) lumateperone, or optionally its acid addition salt. The object of the invention also relates to the amorphous form of the morphologically uniform p-toluenesulfonic acid salt of lumateperone and to the naphthalene-2-sulfonic acid salt of lumateperone, to the 1 :2 stoichiometry salt of lumateperone formed with naphthalene-2-sulfonic acid.